[1]
Kei A, Liberopoulos EN, Elisaf MS. What restricts the clinical use of nicotinic acid? Current vascular pharmacology. 2011 Jul 1:9(4):521-30
[PubMed PMID: 21314634]
[2]
Fricker RA, Green EL, Jenkins SI, Griffin SM. The Influence of Nicotinamide on Health and Disease in the Central Nervous System. International journal of tryptophan research : IJTR. 2018:11():1178646918776658. doi: 10.1177/1178646918776658. Epub 2018 May 21
[PubMed PMID: 29844677]
[3]
Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clinic proceedings. 2008 Apr:83(4):470-8. doi: 10.4065/83.4.470. Epub
[PubMed PMID: 18380993]
[4]
Wierzbicki AS. Niacin: the only vitamin that reduces cardiovascular events. International journal of clinical practice. 2011 Apr:65(4):379-85. doi: 10.1111/j.1742-1241.2011.02630.x. Epub
[PubMed PMID: 21401825]
[5]
Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Current vascular pharmacology. 2011 Jul 1:9(4):385-400
[PubMed PMID: 21314635]
[6]
HOFFER A. Treatment of arthritis by nicotinic acid and nicotinamide. Canadian Medical Association journal. 1959 Aug 15:81(4):235-8
[PubMed PMID: 14402370]
[7]
Xu XJ,Jiang GS, Niacin-respondent subset of schizophrenia – a therapeutic review. European review for medical and pharmacological sciences. 2015;
[PubMed PMID: 25855923]
[8]
Taketani Y, Masuda M, Yamanaka-Okumura H, Tatsumi S, Segawa H, Miyamoto K, Takeda E, Yamamoto H. Niacin and Chronic Kidney Disease. Journal of nutritional science and vitaminology. 2015:61 Suppl():S173-5. doi: 10.3177/jnsv.61.S173. Epub
[PubMed PMID: 26598845]
[9]
Park SM, Li T, Wu S, Li WQ, Weinstock M, Qureshi AA, Cho E. Niacin intake and risk of skin cancer in US women and men. International journal of cancer. 2017 May 1:140(9):2023-2031. doi: 10.1002/ijc.30630. Epub 2017 Feb 14
[PubMed PMID: 28152570]
[10]
Motawi TK, Darwish HA, Hamed MA, El-Rigal NS, Aboul Naser AF. Coenzyme Q10 and niacin mitigate streptozotocin- induced diabetic encephalopathy in a rat model. Metabolic brain disease. 2017 Oct:32(5):1519-1527. doi: 10.1007/s11011-017-0037-x. Epub 2017 May 30
[PubMed PMID: 28560538]
[11]
Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annual review of pharmacology and toxicology. 2008:48():79-106
[PubMed PMID: 17705685]
[12]
Montecucco F, Quercioli A, Dallegri F, Viviani GL, Mach F. New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert review of cardiovascular therapy. 2010 Oct:8(10):1457-67. doi: 10.1586/erc.10.116. Epub
[PubMed PMID: 20936932]
[13]
Meyer-Ficca M, Kirkland JB. Niacin. Advances in nutrition (Bethesda, Md.). 2016 May:7(3):556-8. doi: 10.3945/an.115.011239. Epub 2016 May 16
[PubMed PMID: 27184282]
Level 3 (low-level) evidence
[14]
Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in cell biology. 2014 Aug:24(8):464-71. doi: 10.1016/j.tcb.2014.04.002. Epub 2014 Apr 29
[PubMed PMID: 24786309]
[15]
Li J, Qu J, Shi Y, Perfetto M, Ping Z, Christian L, Niu H, Mei S, Zhang Q, Yang X, Wei S. Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation. Scientific reports. 2017 Mar 3:7():43173. doi: 10.1038/srep43173. Epub 2017 Mar 3
[PubMed PMID: 28256591]
[16]
Yang X, Mei S, Niu H, Li J. Nicotinic acid impairs assembly of leading edge in glioma cells. Oncology reports. 2017 Aug:38(2):829-836. doi: 10.3892/or.2017.5757. Epub 2017 Jun 27
[PubMed PMID: 28656206]
[17]
Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. Vascular health and risk management. 2014:10():279-90. doi: 10.2147/VHRM.S58694. Epub 2014 May 7
[PubMed PMID: 24855368]
[18]
Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vascular health and risk management. 2009:5():901-8
[PubMed PMID: 20016845]
[19]
Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart (British Cardiac Society). 2016 Feb:102(3):198-203. doi: 10.1136/heartjnl-2015-308055. Epub 2015 Sep 14
[PubMed PMID: 26370223]
Level 1 (high-level) evidence